公开(公告)号：EP2297118B1

公开(公告)日：2011-10-05

申请号：EP09745770.9

申请日：2009-05-14

申请人： N.V. Organon

发明人： COOKE, Andrew, John ,  EDWARDS, Andrew, Stanley ,  ANDREWS, Fiona, Elizabeth ,  BENNETT, David, Jonathan ,  NIMZ, Olaf ,  CARSWELL, Emma Louise

IPC分类号： C07D241/04 ,  C07D241/08 ,  C07D243/08 ,  C07D295/192 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  A61K31/551 ,  A61P9/10

CPC分类号： C07D295/192 ,  C07D243/08

摘要： 101 Abstract. The present invention relates tohexafluoroisopropanol derivativeshaving the general formula I X O N N Y OH F 3 C CF 3 A R 1 R 2 R 3 ( ) n W Z B R 6 5 Formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives inthe treatment of atherosclerosis

摘要翻译： 101摘要。 本发明涉及具有通式I的六氟异丙醇衍生物和包含其的药物组合物以及涉及这些六氟异丙醇衍生物在治疗动脉粥样硬化中的用途

公开(公告)号：EP2297118A1

公开(公告)日：2011-03-23

申请号：EP09745770.9

申请日：2009-05-14

申请人： N.V. Organon

发明人： COOKE, Andrew, John ,  EDWARDS, Andrew, Stanley ,  ANDREWS, Fiona, Elizabeth ,  BENNETT, David, Jonathan ,  NIMZ, Olaf ,  CARSWELL, Emma Louise

IPC分类号： C07D243/08 ,  C07D295/192 ,  A61K31/551 ,  A61P9/10

CPC分类号： C07D295/192 ,  C07D243/08

摘要： 101 Abstract. The present invention relates tohexafluoroisopropanol derivativeshaving the general formula I X O N N Y OH F 3 C CF 3 A R 1 R 2 R 3 ( ) n W Z B R 6 5 Formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives inthe treatment of atherosclerosis

公开(公告)号：EP1934212A1

公开(公告)日：2008-06-25

申请号：EP06793916.5

申请日：2006-09-29

申请人： N.V. Organon

发明人： BINGHAM, Matilda, Jane ,  HUGGETT, Margaret, Jean ,  HUGGETT, Mark ,  KIYOI, Yasuko ,  NAPIER, Susan, Elizabeth ,  NIMZ, Olaf

IPC分类号： C07D451/14 ,  A61K31/439 ,  A61P25/24

CPC分类号： C07D451/14

摘要： The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.